Used in the treatment of multiple myeloma, this antibody targets CD38, a protein highly expressed on myeloma cells. It induces cell death through several mechanisms including direct apoptosis, immune-mediated killing, and modulation of enzymatic activity. It is often combined with standard therapies like lenalidomide or dexamethasone to enhance efficacy. Also used as a reference in laboratory research and drug development to evaluate new anti-CD38 agents.